Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients [2]

International Urology and Nephrology

Volumn 40, Issue 1, 2008, Pages 229-230

  Musso, Carlos Guido ^a   Reynaldi, Maria J ^a   Aparicio, Carolina ^a   Frydenlund, Silvina ^a   Imperiali, Nora ^a   Algranati, L ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NICOTINIC ACID; PHOSPHORUS; SODIUM PHOSPHATE COTRANSPORTER;

CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIFFUSION; DRUG WITHDRAWAL; FLUSHING; GASTROINTESTINAL ABSORPTION; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; LETTER; PERITONEAL DIALYSIS; PHOSPHATE INTAKE; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT DURATION;

DELAYED-ACTION PREPARATIONS; HUMANS; HYPERPHOSPHATEMIA; NIACIN; PERITONEAL DIALYSIS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 41549093687     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9306-7     Document Type: Letter

References (3)

1. Hamilton H (ed) (1993) Drug handbook. Springhouse, Pennsylvania
2. Sampathkumar K, Selvam M, Sooraj Y, Gowthaman S, Ajeshkumar R (2006) Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 38:171-174
3. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65(3):1099-1104